BITD 401412
Alternative Names: anti-CD40 antibody - Boston Immune Technologies and Therapeutics; BITD-401412; BITT-101Latest Information Update: 23 Aug 2024
At a glance
- Originator Boston Immune Technologies and Therapeutics
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action CD40 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammation
Most Recent Events
- 18 Aug 2024 Boston Immune Technologies and Therapeutics enters R&D agreement with McQuade Center for Strategic Research and Development for preclinical development of BITD 401412
- 16 Aug 2024 Boston Immune Technologies and Therapeutics announces intention to submit Investigation New Drug (IND) application for Sjogren’s Syndrome in 2025
- 31 Aug 2023 Boston Immune Technologies and Therapeutics plans a phase I trial for Sjogren’s Syndrome